Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,370 JPY | +1.56% | +2.97% | +20.44% |
Apr. 09 | H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy | MT |
Mar. 29 | Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.44% | 21.96B | B+ | ||
+19.62% | 43.34B | B- | ||
+10.86% | 14.09B | - | ||
+13.07% | 13.64B | B+ | ||
+37.46% | 11.43B | B | ||
-8.59% | 6.86B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+8.46% | 5.22B | B+ | ||
-4.29% | 4.71B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4578 Stock
- Ratings Otsuka Holdings Co., Ltd.